09/585,817

June 1, 2000

Schenk, Dale B.

PTO/SB/81 (02-01)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Numb r

First Named Inventor

Filing Date

POWER OF ATTORNEY OR			First Name	d Inventor	Schenk, Dale B.		
AUTHORIZATION CEAGENT			Title		Prevention and Treatment of Amyloidogenic Disease		
			Group Art Unit		1647		
			Examiner Name		Turner, Sharon L.		
			Attorney Docket Number		15270J-005910US		
I hereby appoint:							
□ Practitioners at Customer Number 2035			50	-	Number Bar Code		
OR Label here Practitioner(s) named below:							
	ner(s) nam	Name		Regist	ration Number		

-	 						
-							
L			<u> </u>	1			
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.							
Please change the correspondence address for the above-identified application to:							
	-	ed Customer Number.					
OR							
Practitioners at Customer Number							
Firm or	ıl Name						
Address				J			
City		···		tate	ZIP		
Country							
Telephone			1	Fax			
I am the:							
Applicant/Inventor.							
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name	Kevin Ins	Kevin Insley, Vice President, Neuralab Limited					
Signature 6000 Signature					0		
Date	Date Fenensky 28, 7002						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representatives) are required. Submit multiple forms if more than one signature is required, see below*.							
*Total of 1 forms are submitted.							
G - see of terms of continuous							

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3202741 v1

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Afternovy Decket No. 15270 L 005010 U.S.

Attorney Docket No. 15270J-005910US

STATEMENT UNDER 37 CFR 3.73(b)						
Applicant/Patent Owner: Dale B. Schenk						
Application No./Patent No.: 09/585,817 Filed/Issue Date: June 1, 2000						
Entitled: Prevention and Treatment of Amyloidogenic Disease						
Neuralab Limited , a corporation						
(Name of Assignee) (Type of Assig	nee, e.g., corporation, partnership, university, government agency, etc.)					
states that it is:						
1. X the assignee of the entire right. tte, and interest;	the assignee of the entire right. title, and interest; or					
2. an assignee of less than the entire right, title and in The extent (by, percentage) of its ownership interest.	an assignee of less than the entite right, title and interest. The extent (by, percentage) of its ownership interest is%					
in the patent application/patent identified above by virtue of either:						
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the british dates Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.						
OR						
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:						
 From: <u>Dale B. Schenk</u> To :<u>Elan Pharmaceuticals, Inc.</u> The document was recorded in the United States Patent and Trademark Office at Reel <u>012230</u>, Frame <u>0877</u>, or for which a copy thereof is attached. 						
From: Elan Pharmaceuticals, Inc. To :Neuralab Limited The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0885, or for which a copy thereof is attached.						
3. From: Elan Pharmaceuticals, Inc. To :Neuralab Limited (Nunc Pro Tunc)						
The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0893, or for which a copy thereof is attached.						
Additional documents in the chain of title are listed on a supplemental sheet						
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]						
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.						
FEYLHARY 28, 2002 Date	Typed or printed name CATUMAN Signature					
	Vice President \/ Title					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.